A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) -- a potent immune-boosting protein that holds promise for cancer treatment ...

A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) ⎯ a ...

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...

IMUNON (IMNN) announced the outcome of its recent End-of-Phase 2 in-person meeting with the U.S. Food and Drug Administration, FDA, supporting ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...